Friday, 7 April 2017
Thursday, 6 April 2017
RedHill Biopharma Receives FDA Orphan Drug Designation for YELIVA® for the Treatment of Cholangiocarcinoma
TEL-AVIV, Israel, April 5 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted YELIVA® (ABC294640) Orphan Drug designation for the treatment of cholangiocarcinoma.
The Orphan Drug designation allows RedHill to benefit from various development incentives to develop YELIVA® for this indication, including tax credits for qualified clinical testing, waiver of a prescription drug user fee (PDUFA fee) upon submission of a potential marketing application and, if approved, a seven-year marketing exclusivity period for the treatment of cholangiocarcinoma.
YELIVA® is a Phase II-stage, proprietary, first-in-class, orally-administered sphingosine kinase-2 (SK2) selective inhibitor with anticancer and anti-inflammatory activities, targeting multiple oncology, inflammatory and gastrointestinal indications. By inhibiting the SK2 enzyme, YELIVA® blocks the synthesis of sphingosine 1-phosphate (S1P), a lipid signaling molecule that promotes cancer growth and pathological inflammation.
SOURCE : RedHill Biopharma Ltd.
Wednesday, 5 April 2017
TGS ANNOUNCES FURTHER EXPANSION OF NORTH-WEST AFRICAN ATLANTIC MARGIN 2D SEISMIC SURVEY
ASKER, Norway, April 4 (Bernama-GLOBE NEWSWIRE) -- TGS announces a further expansion of its NWAAM multi-client library in the MSGBC Basin with plans to acquire more than 11,000 km of long-offset broadband 2D seismic data together with magnetic and gravity data, in Senegal and Gambia. This expansion is being undertaken in cooperation with Petrosen in Senegal and the Ministry of Petroleum and Energy in Gambia. The investment is being undertaken together with PGS and GeoPartners. Acquisition of this further phase of NWAAM 2017 has commenced and continues seamlessly from Phase 1. The NWAAM 2017 seismic survey has been designed to infill, extend and complement the TGS NWAAM 2012 2D survey which helped with recent commercial discoveries in the MSGBC basin. A 12 km deep-tow streamer will enable the recording of high quality broadband 2D seismic data, which will image the pre-rift, syn-rift and post-rift plays evident in this basin.
"This further expansion of our NWAAM data library confirms TGS' continued commitment to the leading frontier basin in Africa. We are excited to be part of the ongoing exploration and upcoming development of this basin,” commented Kristian Johansen, CEO for TGS.
This survey is supported by industry funding and is being undertaken with the seismic vessel, BGP Dong Fang Kan Tan 1.
A PDF accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/8055ea29-20a6-4093-acc6-6d212f0bac2f
Company Summary
TGS-NOPEC Geophysical Company (TGS) provides multi-client geoscience data to oil and gas Exploration and Production companies worldwide. In addition to extensive global geophysical and geological data libraries that include multi-client seismic data, magnetic and gravity data, digital well logs, production data and directional surveys, TGS also offers advanced processing and imaging services, interpretation products, and data integration solutions.
For more information visit TGS online at www.tgs.com.
Forward-looking statements and contact information
All statements in this press release other than statements of historical fact are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that are difficult to predict, and are based upon assumptions as to future events that may not prove accurate. These factors include TGS' reliance on a cyclical industry and principle customers, TGS' ability to continue to expand markets for licensing of data, and TGS' ability to acquire and process data products at costs commensurate with profitability. Actual results may differ materially from those expected or projected in the forward-looking statements. TGS undertakes no responsibility or obligation to update or alter forward-looking statements for any reason.
TGS-NOPEC Geophysical Company ASA is listed on the Oslo Stock Exchange (OSLO:TGS).
TGS sponsored American Depositary Shares trade on the U.S. over-the-counter market under the symbol "TGSGY".
For additional information about this press release please contact:
Sven Børre Larsen
Chief Financial Officer
Tel: +47 90 94 36 73
Email: sven.larsen@tgs.com
Will Ashby
VP HR & Communication
Tel: +1 713 860 2184
Email: will.ashby@tgs.com
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
SOURCE : TGS
--BERNAMA
"This further expansion of our NWAAM data library confirms TGS' continued commitment to the leading frontier basin in Africa. We are excited to be part of the ongoing exploration and upcoming development of this basin,” commented Kristian Johansen, CEO for TGS.
This survey is supported by industry funding and is being undertaken with the seismic vessel, BGP Dong Fang Kan Tan 1.
A PDF accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/8055ea29-20a6-4093-acc6-6d212f0bac2f
Company Summary
TGS-NOPEC Geophysical Company (TGS) provides multi-client geoscience data to oil and gas Exploration and Production companies worldwide. In addition to extensive global geophysical and geological data libraries that include multi-client seismic data, magnetic and gravity data, digital well logs, production data and directional surveys, TGS also offers advanced processing and imaging services, interpretation products, and data integration solutions.
For more information visit TGS online at www.tgs.com.
Forward-looking statements and contact information
All statements in this press release other than statements of historical fact are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that are difficult to predict, and are based upon assumptions as to future events that may not prove accurate. These factors include TGS' reliance on a cyclical industry and principle customers, TGS' ability to continue to expand markets for licensing of data, and TGS' ability to acquire and process data products at costs commensurate with profitability. Actual results may differ materially from those expected or projected in the forward-looking statements. TGS undertakes no responsibility or obligation to update or alter forward-looking statements for any reason.
TGS-NOPEC Geophysical Company ASA is listed on the Oslo Stock Exchange (OSLO:TGS).
TGS sponsored American Depositary Shares trade on the U.S. over-the-counter market under the symbol "TGSGY".
For additional information about this press release please contact:
Sven Børre Larsen
Chief Financial Officer
Tel: +47 90 94 36 73
Email: sven.larsen@tgs.com
Will Ashby
VP HR & Communication
Tel: +1 713 860 2184
Email: will.ashby@tgs.com
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
SOURCE : TGS
--BERNAMA
TACONIC BIOSCIENCES LAUNCHES EXPRESSMODEL™, A NEW ACCELERATED MODEL GENERATION SERVICE
HUDSON, N.Y., April 4 (Bernama-GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in genetically engineered mouse models and associated services, has launched ExpressMODEL™, an innovative and streamlined model generation service that reduces the timeline to first generation and experimental cohort by up to four months.
This novel model generation method significantly reduces the time required to create an experimental rodent cohort, enabling critical drug discovery testing to happen much faster, saving both time and money.
ExpressMODEL™ leverages Taconic’s extensive in vitro fertilization (IVF) expertise, optimizing procedures by using chimaeras to rapidly expand founder mice. This increases the number of mice carrying targeted alleles in the first generation from 3-4 to at least 20-30. By providing a sizeable colony of first generation heterozygous animals, ExpressMODEL™ allows researchers to skip at least one round of colony expansion, saving 3-4 months on the overall project timeline. Elimination of natural breeding in the germline transmission step results in predictable timelines and better experiment planning.
Unlike other methods employed to reduce timelines, ExpressMODEL™ does not rush critical genome modification procedures. The new Taconic approach preserves the use of stringent controls during the genome modification process, thereby minimizing the risk of generating a mouse model carrying the wrong transgenic allele or additional unwanted mutations.
“In drug discovery it is rare to find an innovation that saves time while increasing quality, as typically one is pursued at the expense of the other. ExpressMODEL™ represents a tremendous value for our customers because it can save up to four months of time, while creating more predictable timelines and consistent high quality,” shared John Couse, PhD, Portfolio Director for Taconic Scientific Services.
“Our model generation work is not done when we have a founder or breeding pair. With ExpressMODEL™, we provide our clients with research-ready cohorts so they can start their work immediately,” said Couse.
Taconic is a fully-licensed provider of rodent model generation services and has twenty years of model design experience, providing gene inactivation, gene mutation or replacement, transgene expression, RNAi, and gene editing via CRISPR/Cas9 technologies to ensure that the right tools are leveraged for each specific customer project. Complimenting this expertise is Taconic’s unique capability of providing a seamless transition from model design to breeding and colony management, thus offering customers a complete solution. These scientific services include acquiring or generating, importing, licensing, breeding, testing, preparing, and distributing genetically engineered models to any location worldwide.
To learn more about Taconic's custom model generation, please call 1-888-TACONIC (888-822-6642) in the US, or +45 70 23 04 05 in Europe, or email info@taconic.com.
About Taconic Biosciences, Inc.
Taconic Biosciences is a fully-licensed, global leader in genetically engineered rodent models and services. Founded in 1952, Taconic helps biotechnology companies and institutions acquire, custom generate, breed, precondition, test, and distribute valuable research models worldwide. Specialists in genetically engineered mouse and rat models, precision research mouse models, and integrated model design and breeding services, Taconic operates three service laboratories and six breeding facilities in the U.S. and Europe, maintains distributor relationships in Asia and has global shipping capabilities to provide animal models almost anywhere in the world.
Media Contact:
Kelly Owen Grover
Director of Marketing Communications
(518) 697-3824
kelly.grover@taconic.com
SOURCE : Taconic Biosciences
--BERNAMA
This novel model generation method significantly reduces the time required to create an experimental rodent cohort, enabling critical drug discovery testing to happen much faster, saving both time and money.
ExpressMODEL™ leverages Taconic’s extensive in vitro fertilization (IVF) expertise, optimizing procedures by using chimaeras to rapidly expand founder mice. This increases the number of mice carrying targeted alleles in the first generation from 3-4 to at least 20-30. By providing a sizeable colony of first generation heterozygous animals, ExpressMODEL™ allows researchers to skip at least one round of colony expansion, saving 3-4 months on the overall project timeline. Elimination of natural breeding in the germline transmission step results in predictable timelines and better experiment planning.
Unlike other methods employed to reduce timelines, ExpressMODEL™ does not rush critical genome modification procedures. The new Taconic approach preserves the use of stringent controls during the genome modification process, thereby minimizing the risk of generating a mouse model carrying the wrong transgenic allele or additional unwanted mutations.
“In drug discovery it is rare to find an innovation that saves time while increasing quality, as typically one is pursued at the expense of the other. ExpressMODEL™ represents a tremendous value for our customers because it can save up to four months of time, while creating more predictable timelines and consistent high quality,” shared John Couse, PhD, Portfolio Director for Taconic Scientific Services.
“Our model generation work is not done when we have a founder or breeding pair. With ExpressMODEL™, we provide our clients with research-ready cohorts so they can start their work immediately,” said Couse.
Taconic is a fully-licensed provider of rodent model generation services and has twenty years of model design experience, providing gene inactivation, gene mutation or replacement, transgene expression, RNAi, and gene editing via CRISPR/Cas9 technologies to ensure that the right tools are leveraged for each specific customer project. Complimenting this expertise is Taconic’s unique capability of providing a seamless transition from model design to breeding and colony management, thus offering customers a complete solution. These scientific services include acquiring or generating, importing, licensing, breeding, testing, preparing, and distributing genetically engineered models to any location worldwide.
To learn more about Taconic's custom model generation, please call 1-888-TACONIC (888-822-6642) in the US, or +45 70 23 04 05 in Europe, or email info@taconic.com.
About Taconic Biosciences, Inc.
Taconic Biosciences is a fully-licensed, global leader in genetically engineered rodent models and services. Founded in 1952, Taconic helps biotechnology companies and institutions acquire, custom generate, breed, precondition, test, and distribute valuable research models worldwide. Specialists in genetically engineered mouse and rat models, precision research mouse models, and integrated model design and breeding services, Taconic operates three service laboratories and six breeding facilities in the U.S. and Europe, maintains distributor relationships in Asia and has global shipping capabilities to provide animal models almost anywhere in the world.
Media Contact:
Kelly Owen Grover
Director of Marketing Communications
(518) 697-3824
kelly.grover@taconic.com
SOURCE : Taconic Biosciences
--BERNAMA
WOMEN, SENIORS AND INDEPENDENT PROFESSIONALS RESHAPE THE LATIN AMERICAN TRAVEL LANDSCAPE
SÃO PAULO, April 5 (Bernama-BUSINESS WIRE) -- Global market research company Euromonitor International released today the 2017 WTM Latin America Trends Report at World Travel Market (WTM) Latin America, revealing how the regional travel industry is developing amidst socioeconomic changes.
The three most prominent trends identified by the report are:
Ageing travellers
Forecasted to represent 28 percent of the total Latin American tourists, over 50s will add 90 million people to the market by 2020. With more time on their hands and specific needs, this fast-growing group represents an opportunity to boost low season tourism and create tailored services.
http://mrem.bernama.com/viewsm.php?idm=28835
The three most prominent trends identified by the report are:
Ageing travellers
Forecasted to represent 28 percent of the total Latin American tourists, over 50s will add 90 million people to the market by 2020. With more time on their hands and specific needs, this fast-growing group represents an opportunity to boost low season tourism and create tailored services.
http://mrem.bernama.com/viewsm.php?idm=28835
ESTABLISHMENT OF MITSUI CHEMICALS THAILAND
--Seeking to Bolster Local Marketing Power--
Before the establishment of Mitsui Chemicals Thailand, Mitsui Chemicals had six manufacturing and sales bases in Thailand. With this distributor in the important Thai market, Mitsui Chemicals will strengthen its operations in Thailand through local-based marketing and will expand sales in neighboring countries.
TOKYO, April 3 (Bernama-BUSINESS WIRE) -- Mitsui Chemicals, Inc. (Tokyo: 4183; President & CEO: Tsutomu Tannowa) announced that it established Mitsui Chemicals (Thailand) Co., Ltd. in Bangkok, Thailand on April 3, 2017. With Mitsui Chemicals (Thailand) Co., Ltd. functioning as the Mitsui Chemicals Group distributor in Thailand, Mitsui Chemicals will bolster its marketing power and expand its business.
Background of the establishment
An important market in Southeast Asia in the auto and packaging materials industries, Thailand is particularly vital for Mitsui Chemicals’ core Mobility and Food & Packaging businesses. Thailand has a concentration of major global companies in the field of health care, particularly spectacle lens materials. Mitsui Chemicals can thus expand in Thailand its Health Care business, another core business.
| Outline of Mitsui Chemicals (Thailand) Co., Ltd. | ||
| Company name | Mitsui Chemicals (Thailand) Co., Ltd. | |
| Establishment | April 3, 2017 | |
| Capital | 150 million bahts (Mitsui Chemicals 100%) | |
| Location | Bangkok | |
| President | Toshihiro Motoshima | |
| Product | Sales and Marketing of Mitsui Chemicals products | |
| Commercial Operation | July 2017 | |
An important market in Southeast Asia in the auto and packaging materials industries, Thailand is particularly vital for Mitsui Chemicals’ core Mobility and Food & Packaging businesses. Thailand has a concentration of major global companies in the field of health care, particularly spectacle lens materials. Mitsui Chemicals can thus expand in Thailand its Health Care business, another core business.
Before the establishment of Mitsui Chemicals Thailand, Mitsui Chemicals had six manufacturing and sales bases in Thailand. With this distributor in the important Thai market, Mitsui Chemicals will strengthen its operations in Thailand through local-based marketing and will expand sales in neighboring countries.
FOOMA JAPAN 2017, ASIA'S LARGEST TRADE SHOW OF FOOD MACHINERY AND FOOD-PROCESSING TECHNOLOGY, SET FOR JUNE 13-16 IN TOKYO
TOKYO, April 5 (Bernama-AsiaNet) --
| - Expanded, Enhanced Exhibition for over 100,000 Visitors - The International Food Machinery & Technology Exhibition (FOOMA JAPAN), a comprehensive trade show for food machinery and food-processing technologies, will be held from June 13 (Tue.) to 16 (Fri.), 2017, in Tokyo, this time with further expanding its exhibition area to roughly 15,000 square meters. It brings together exhibiting companies in all fields of the food manufacturing process, from raw material processing to packaging and distribution, focused on food manufacturing and processing machinery. This year marks the 40th anniversary of this annual exhibition that has a long history and tradition in Japan. Over 700 corporations will take part in FOOMA JAPAN, which speaks to its size as one of the largest exhibitions in Asia. This lively exhibition is visited by almost 100,000 people each time, and more overseas visitors are coming every year in search of excellent food-manufacturing and processing machinery. (Photo: http://prw.kyodonews.jp/prwfile/release/M104335/201703240256/_prw_PI1fl_WVz4e0Ur.jpg) A broad range of world-renowned, cutting-edge Japanese technologies FOOMA JAPAN 2017 will bring together cutting-edge products, technologies, services and information on the theme of "The Compass for the Future of Food." It will feature world-renowned, cutting-edge food-processing technologies from Japan that boost production efficiency and quality, as well as technologies related to safety and health, energy conservation, and the environment. Visitors can also view and interact with many real machinery demonstrations that closely resemble foodstuff factories and also sample foods. Many of these exhibitions are of machinery for manufacturing Japanese foods that are popular overseas, such as sushi and noodles, as well as food-manufacturing robotic systems developed by world-renowned Japanese manufacturers specialized in industrial robots. Dedicated venue support for overseas visitors FOOMA JAPAN offers a wide range of services to visitors from overseas countries. Inside the venue, exhibiting company staff members who can speak English, Chinese, Korean and other languages wear "Bilingual Badges" on their chests. English-, Chinese-, and Korean-speaking staff members are also stationed at the Information Desk to answer inquiries and questions from visitors. Moreover, visitors can relax and enjoy free drinks at the International Lounge. Venue photographs, exhibiting company names and exhibited products from FOOMA JAPAN 2016 are available on the official website, where you can get a sense of the overwhelming scale of FOOMA JAPAN, one of Asia's largest exhibitions. Pre-registration for visitors began for FOOMA JAPAN 2017 on April 3, 2017, on the official website (http://www.foomajapan.jp/english/index.html), where you can also make hotel reservations. Please check the website for the latest information on this wide range of services. About organizer The Japan Food Machinery Manufacturers' Association (FOOMA) was established in 1948 (received recognition as a corporation in March 1967 by the Ministry of International Trade and Industry, currently the Ministry of Economy, Trade and Industry) to develop the Japanese food machinery industry. FOOMA is organized by leading Japanese food machinery manufacturers and the sole association for Japanese food machinery industry in Japan. Lately, FOOMA has nearly 400 members and focus on their missions not only for development of the Japanese food machinery industry but also for contribution to healthy life in the whole world by Japanese food technology. SOURCE: The Japan Food Machinery Manufacturers' Association --BERNAMA |
Subscribe to:
Posts (Atom)